Further complicating the treatment landscape, resistance to PD-1 inhibitors in lung cancer has been correlated with upregulation of other immune checkpoints such as TIM-3 and LAG-3 in mouse models (14). The gene discussed is HAVCR2; the disease is lung carcinoma.